drugset / Trial / NCT04340050

COVID-19 Convalescent Plasma

NCT04340050 ↗

Phase 0 Completed 10 enrolled University of Chicago
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the feasibility of delivering anti-SARS-CoV-2 convalescent plasma to hospitalized patients with severe or life-threatening COVID-19. Beyond supportive care, there are currently no proven treatment options for coronavirus disease (COVID-19), the infection caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Human convalescent plasma is an option for treatment of COVID-19 and could be rapidly available when there are sufficient numbers of people who have recovered and can donate high titer neutralizing immunoglobulin-containing plasma. Hypothesis: Collecting and administering convalescent plasma requires a level of logistical coordination that is not available in all centers. Objective: To establish feasibility for a hospital-based integrated system to collect and administer convalescent plasma to patients with severe or life-threatening COVID-19.

Timeline

Start
2020-04-10
Primary completion
2020-12-23
Completion
2020-12-23

Drugs

EvaluationDrugModalityDoseRoute
Subject anti-SARS-CoV-2 convalescent plasma Protein / enzyme biologic 300 ml —